Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Drug Discovery Development" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Drug Discovery Development for you to read. Along with our medical data and news we also list Drug Discovery Development Clinical Trials, which are updated daily. BioPortfolio also has a large database of Drug Discovery Development Companies for you to search.
NewsBoehringer Ingelheim announced that an expanded indication for SPIRIVA Respimat (tiotropium Respimat) as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the past year, has been accepted by the regulatory authorities in the EU.
News President Donald Trump’s plan to combat opioid drug addiction nationwide calls for stiffer penalties for drug traffickers, including the death penalty where appropriate under current law, a top administration official said.
NewsA new birth control pill for men appears to be safe when used daily for a month, with hormone responses consistent with effective contraception, study researchers say.
NewsThe House plans to try anew next week to approve a Republican bill making it simpler for fatally ill people to try unproven treatments. And this time, the measure seems certain to pass.
NewsResearchers achieved an 80% reduction in liver metastasis brought about by colon cancer. Nanoparticles were used to slow down the growth of the blood vessels that reach the tumor cells.
NewsA statistical analysis of the first three years of the study showed there was no chance the drug would work. The test was costing hundreds of millions of dollars with no hope it would ever help patients or come to market. Another promising anti-Alzheimer’s drug had failed.
NewsOverdose deaths in Native American communities have skyrocketed in the time the opioid epidemic has swept the U.S. and federal officials are looking for solutions.
NewsErdafitinib, an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, shows promise as the first targeted agent for patients with metastatic urothelial cancer, one of the most common cancers.
NewsBoehringer Ingelheim and Vanderbilt University announced the expansion of their successful existing collaboration to develop novel anti-cancer compounds.
NewsA precision medicine approach will focus efforts on high-risk patients, such as those who have had heart attacks or unstable angina and cannot reduce their LDL-C below 100 mg/dL despite maximally-tolerated statins.
NewsAbbVie, in cooperation with Neurocrine Biosciences, Inc., announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint.
NewsEven though the Shh pathway is mainly quiescent in adults, the safety of Shh-targeting with therapeutic antibodies was questioned initially because not only does the N-terminus of the Shh protein play an important role in embryonic development, but Shh also plays a poorly understood role in tissue homeostasis and repair in adults.
NewsIn a paper published in the Open Access, peer-reviewed journal Journal of Spectral Imaging, the authors report on the use of NIR chemical imaging for in-line feed frame monitoring.
NewsThe anti-inflammatory drug canakinumab had no effect on rates of newly diagnosed diabetes in people who had prediabetes (elevated blood sugar levels at risk of developing into diabetes).
NewsResearchers have discovered that a blood-thinning drug, dabigatran, significantly reduces the risk of death, heart attack, stroke, and other heart or blood-vessel complications in patients who have a heart injury following major, non-cardiac surgery.
NewsMerck announced that the U.S. Food and Drug Administration (FDA) has accepted a new supplemental Biologics License Application (sBLA) and granted Priority Review for KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy.
NewsFebuxostat, a gout drug that has been in use for nearly a decade, was found to significantly increase the risk of death, even though it did not raise the risk of the trial’s primary endpoint, a combined rate of fatal and nonfatal adverse cardiovascular events.
NewsA smartphone app that lets Medicare patients access their claims information. Giving consumers a share of drug company rebates for their prescriptions. Wider access to websites that reliably compare cost and quality of medical tests.
NewsThe Janssen Pharmaceutical Companies of Johnson & Johnson announced results of a new analysis showing that INVOKANA (canagliflozin) significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) at high CV risk.
NewsA real-world evidence study of more than 400,000 patients with type-2 diabetes, 74% of whom did not have a history of established cardiovascular disease, supports the association of CV benefits with use of Farxiga.
NewsResearchers have been working with ubiquitin, a tiny molecule that tags obsolete proteins in a cell. They recently found that ubiquitin eliminates droplets of Ubiquilin-2 (UBQLN2) in solution.
NewsGlaxoSmithKline and Innoviva announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid/long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
NewsAmgen announced data from two new studies exploring barriers to access for PCSK9 inhibitors and the potential consequences of denying coverage for high-risk patients.
NewsAn herbalist who touted natural cures that helped him overcome cancer has been charged in the death of a 13-year-old diabetic boy who prosecutors said he treated with herbal oils instead of insulin.
NewsThe FDA approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past and whose HIV infections cannot be successfully treated with other currently available therapies.